SRT3-22.5 Slow Release T3 (22.5mcg)
New 2026 Formulation
Updated slow-release matrix for improved bioavailability
HPMC + MCC Only · 4-8 Hour Release
Two-excipient formulation, minimal allergen and MCAS-trigger profile
Slow-release T3 (22.5mcg, 50 tablets), used in research on sustained T3 availability and Wilson's Temperature Syndrome protocols.
Storage & Handling
Once opened, this product should be used within 60 days because its excipient ingredients, Microcrystalline Cellulose (MCC) and Hydroxypropyl Methylcellulose (HPMC), act like sponges that easily absorb water vapor from the air. Every time you open and close the bottle, ambient humidity gets trapped inside, which gradually degrades potency. To protect it, always leave the silica desiccant packet inside the bottle to soak up stray moisture, tightly seal the lid immediately after use, and store it on a counter at room temperature away from excessive heat or humid spots like bathrooms.
Molecular Characteristics
Minimalist Excipient Profile
SRT3 uses only two excipients: hydroxypropyl methylcellulose (HPMC) and microcrystalline cellulose (MCC). HPMC provides the matrix that extends T3 release over a 4-8 hour window; MCC serves as the inert filler. No dyes, fillers, gums, lactose, gluten, or surfactants commonly found in compounded T3 formulations. This minimal profile is intended for research subjects with sensitivities to common excipients (MCAS, mast cell, or multi-allergen research models).
Research Use Only
For laboratory research use only. Not for human or animal consumption, diagnostic, or therapeutic use.
Discreet Shipping
Discreet plain-label packaging.
Questions about customs in your country? Reach out to your Chronic Illness Store representative - or if you've lost contact, email us directly.